Botox (Allergan) approved by MHRA in UK for Urinary Incontinence
The Medicines and Healthcare products Regulatory Agency (MHRA)in the UK has given Botox (botulinum toxin type A) approval for managing Urinary Incontinence caused by neurogenic detrusor overactivity(NDO) due to subcervical spinal cord injury (SCI; traumatic or non-traumatic) or multiple sclerosis (MS), but only if treatment with anticholinergics does not work. Recently published NICE Guidelines recommend the use of botulinum toxin type A to treat patients with MS or SCI who have symptoms of an overactive bladder and in whom oral treatments have been ineffective or poorly tolerated.
Around 140,000 people in the UK are living with MS and SCI, of which between 75%-80% and 60%-80%, respectively, will suffer some degree of bladder dysfunction, including urinary leakage, caused by involuntary contractions of the bladder.
Related news and insights
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from the Phase IIIb COSMOS clinical trial showing that treatment with Tremfya (guselkumab) provided sustainable improvements in all minimal disease activity (MDA)a domains through week 48 in adults living with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR)
Pfizer Inc. announced the first detailed results from the Phase II PHAROS study, which is evaluating the efficacy and safety of Braftovi (encorafenib) given in combination with Mektovi(binimetinib) to patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)
Legend Biotech Corp announced that results from the Phase III CARTITUDE-4 study showed that, at a median follow up of 16 months, cilta-cel (ciltacabtagene autoleucel) reduced the risk of disease progression or death by 74 percent compared to standard of care regimens in adult patients with multiple myeloma who have received one to three prior lines of therapy and are refractory to lenalidomide (Hazard ratio [HR]=0.26 (95% CI, 0.18–0.38); P-value [P] <0.0001)